2022 Form 10-K Financial Statement
#000149315222018006 Filed on June 29, 2022
Income Statement
Concept | 2022 | 2021 |
---|---|---|
Revenue | $0.00 | $873.2K |
YoY Change | -100.0% | -37.18% |
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $18.41M | $10.47M |
YoY Change | 75.84% | 17.89% |
% of Gross Profit | ||
Research & Development | $11.80M | $12.62M |
YoY Change | -6.47% | 18.48% |
% of Gross Profit | ||
Depreciation & Amortization | $352.0K | $211.0K |
YoY Change | 66.84% | 31.86% |
% of Gross Profit | ||
Operating Expenses | $30.21M | $23.09M |
YoY Change | 30.85% | 18.21% |
Operating Profit | -$40.71M | |
YoY Change | ||
Interest Expense | -$915.0K | -$661.2K |
YoY Change | 38.38% | -66.09% |
% of Operating Profit | ||
Other Income/Expense, Net | -$3.350M | |
YoY Change | ||
Pretax Income | -$44.06M | -$22.87M |
YoY Change | 92.61% | 13.8% |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | -$43.18M | -$22.87M |
YoY Change | 88.76% | 14.72% |
Net Earnings / Revenue | -2619.67% | |
Basic Earnings Per Share | -$1.68 | |
Diluted Earnings Per Share | -$1.682M | -$1.270M |
COMMON SHARES | ||
Basic Shares Outstanding | 25.67M shares | |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2022 | 2021 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $80.24M | $34.63M |
YoY Change | 131.71% | 74.64% |
Cash & Equivalents | $80.24M | $34.63M |
Short-Term Investments | ||
Other Short-Term Assets | $11.75M | $2.126M |
YoY Change | 452.67% | -68.37% |
Inventory | $350.0K | |
Prepaid Expenses | ||
Receivables | ||
Other Receivables | ||
Total Short-Term Assets | $92.95M | $37.22M |
YoY Change | 149.7% | 39.52% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $4.211M | $2.790M |
YoY Change | 50.95% | 720.51% |
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $206.0K | $137.9K |
YoY Change | 49.41% | |
Total Long-Term Assets | $6.254M | $3.302M |
YoY Change | 89.38% | 340.31% |
TOTAL ASSETS | ||
Total Short-Term Assets | $92.95M | $37.22M |
Total Long-Term Assets | $6.254M | $3.302M |
Total Assets | $99.20M | $40.53M |
YoY Change | 144.78% | 47.74% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $1.129M | $1.325M |
YoY Change | -14.79% | -41.37% |
Accrued Expenses | $8.655M | $1.918M |
YoY Change | 351.23% | 63.94% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $927.0K | $556.5K |
YoY Change | 66.57% | 63.68% |
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $10.71M | $3.800M |
YoY Change | 181.93% | -21.98% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $200.0K | $4.472M |
YoY Change | -95.53% | 3.05% |
Other Long-Term Liabilities | $10.08M | $1.789M |
YoY Change | 463.19% | 1276.51% |
Total Long-Term Liabilities | $10.28M | $6.262M |
YoY Change | 64.14% | 40.08% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $10.71M | $3.800M |
Total Long-Term Liabilities | $10.28M | $6.262M |
Total Liabilities | $26.50M | $10.06M |
YoY Change | 163.34% | 7.72% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | ||
YoY Change | ||
Common Stock | ||
YoY Change | ||
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $72.70M | $30.46M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $99.20M | $40.53M |
YoY Change | 144.78% | 47.74% |
Cashflow Statement
Concept | 2022 | 2021 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$43.18M | -$22.87M |
YoY Change | 88.76% | 14.72% |
Depreciation, Depletion And Amortization | $352.0K | $211.0K |
YoY Change | 66.84% | 31.86% |
Cash From Operating Activities | -$23.13M | -$19.64M |
YoY Change | 17.79% | 28.78% |
INVESTING ACTIVITIES | ||
Capital Expenditures | -$1.380M | -$890.4K |
YoY Change | 54.98% | 2126.03% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | -$70.00K | |
YoY Change | ||
Cash From Investing Activities | -$1.450M | -$890.4K |
YoY Change | 62.85% | -120.15% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 79.45M | 30.33M |
YoY Change | 161.93% | -13.16% |
NET CHANGE | ||
Cash From Operating Activities | -23.13M | -19.64M |
Cash From Investing Activities | -1.450M | -890.4K |
Cash From Financing Activities | 79.45M | 30.33M |
Net Change In Cash | 54.87M | 9.803M |
YoY Change | 459.71% | -59.33% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$23.13M | -$19.64M |
Capital Expenditures | -$1.380M | -$890.4K |
Free Cash Flow | -$21.75M | -$18.75M |
YoY Change | 16.03% | 23.27% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
USD | |
CY2021Q1 | us-gaap |
Other Long Term Debt
OtherLongTermDebt
|
USD | |
CY2021Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
CY2021Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
USD | |
CY2021Q1 | us-gaap |
Minority Interest
MinorityInterest
|
USD | |
CY2021 | XAIR |
Settlement Expense Contingent On Fda Approval
SettlementExpenseContingentOnFdaApproval
|
USD | |
CY2021 | XAIR |
Estimated Liability For Contingent Loss
EstimatedLiabilityForContingentLoss
|
USD | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
USD | |
CY2021 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
USD | |
CY2021 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
USD | |
CY2021 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
USD | |
CY2021 | XAIR |
Issuance Of Vested Restricted Stock
IssuanceOfVestedRestrictedStock
|
USD | |
CY2022 | XAIR |
Stock Issued During Period Value Issuance Of Common Stock Upon Excise Of Warrants Cashless
StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExciseOfWarrantsCashless
|
USD | |
CY2022 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
USD | |
CY2022 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
USD | |
CY2021 | XAIR |
Amortization Of Licensed Right To Use Technology
AmortizationOfLicensedRightToUseTechnology
|
USD | |
CY2022 | XAIR |
Gain On Cancellation Of Operating Lease
GainOnCancellationOfOperatingLease
|
USD | |
CY2021 | XAIR |
Increase Decrease Accrued Liabilities
IncreaseDecreaseAccruedLiabilities
|
USD | |
CY2022 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
USD | |
CY2021 | XAIR |
Security Deposits Made On Rental Properties
SecurityDepositsMadeOnRentalProperties
|
USD | |
CY2021 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
USD | |
CY2021 | XAIR |
Accelerated Amortization Of Debt Discount Costs On Retirement Of Debt
AcceleratedAmortizationOfDebtDiscountCostsOnRetirementOfDebt
|
USD | |
CY2021 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
USD | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
shares | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
||
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
USD | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
|
shares | |
CY2022 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
||
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
shares | |
CY2022 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
||
CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
shares | |
CY2022Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
||
CY2022Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
USD | |
CY2021Q1 | XAIR |
Accruals For Contingent Liabilities
AccrualsForContingentLiabilities
|
USD | |
CY2021Q1 | XAIR |
Accrued Circassia Settlement First Payments Due
AccruedCircassiaSettlementFirstPaymentsDue
|
USD | |
CY2021Q1 | XAIR |
Accrued Nitricgen Agreement Post Fda Approvals
AccruedNitricgenAgreementPostFdaApprovals
|
USD | |
CY2021Q1 | XAIR |
Accrued Circassia Settlement Payment Due
AccruedCircassiaSettlementPaymentDue
|
USD | |
CY2021Q1 | us-gaap |
Other Long Term Debt
OtherLongTermDebt
|
USD | |
CY2022Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
USD | |
CY2022Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
USD | |
CY2022Q1 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
USD | |
CY2021Q1 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
USD | |
CY2022Q1 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
USD | |
CY2021Q1 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
USD | |
CY2021 | XAIR |
Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
|
pure |